{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:49:40Z","timestamp":1795016980573,"version":"4.10.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Expression of CD30 in blastoid cutaneous infiltrates typically signifies a CD30<jats:sup>+<\/jats:sup> lymphoproliferative disorder, often requiring minimal immunohistochemical workup, if clinically consonant. However, myeloid and other hematologic malignancies often express CD30. We retrospectively examined the prevalence of CD30 expression in 41 patients (median age 59) and 55 biopsies with the diagnosis of leukemia cutis (LC) to determine whether an extensive immunohistochemical workup is warranted in all large, round cell CD30<jats:sup>+<\/jats:sup> cutaneous infiltrates. Each patient had refractory or recurrent disease, the histologic presence of a large mononuclear cell infiltrate, and varied cytogenetics. CD30<jats:sup>+<\/jats:sup> mononuclear cells within the infiltrate ranged from rare to many in 22 biopsies (22\/55). In 18 biopsies, CD30<jats:sup>+<\/jats:sup> cells were interpreted as lymphocytic based on morphology, strong cytoplasmic and Golgi staining for CD30, and negative CD34 and CD117 staining. One case showing 3+ staining of lymphocytes was identified as a posttransplant lymphoproliferative disorder. The second 3+ case was favored to represent a subset of CD30-positive acute myeloid leukemia. Three other cases with 1+ membranous and cytoplasmic staining were interpreted as myeloid leukemia. In conclusion, CD30 positivity in myeloid leukemia in the skin is rare and does not often exhibit the strong membranous (2+ or 3+) and\/or Golgi staining seen in reactive lymphocytes. Acute myeloid leukemia or myeloid LC may occasionally show 1+ (and rarely 2\u20133+) cytoplasmic\/membranous or nonspecific blush nuclear CD30 labeling. Strong diffuse staining for CD30 should prompt consideration of a reactive lymphoid\/lymphoproliferative process, and, when the clinical likelihood of CD30<jats:sup>+<\/jats:sup> LC is low, may obviate the need for further immunohistochemistry.<\/jats:p>","DOI":"10.1097\/dad.0000000000000755","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T16:41:49Z","timestamp":1479919309000},"page":"351-357","source":"Crossref","is-referenced-by-count":4,"title":["CD30 Expression Is Rare in Myeloid Leukemia Cutis: A Study of 55 Cases and Implications for Routine Diagnostic Algorithms"],"prefix":"10.1097","volume":"39","author":[{"given":"Olakunle","family":"Ogunrinade","sequence":"first","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Terrano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pulitzer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0888-7543(05)80203-4","article-title":"Assignment of the human CD30 (Ki-1) gene to 1p36","volume":"14","author":"Fonatsch","year":"1992","journal-title":"Genomics"},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","article-title":"CD30: expression and function in health and disease","volume":"10","author":"Horie","year":"1998","journal-title":"Semin Immunol."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/978-0-387-89520-8_12","article-title":"Targeting CD30\/CD30L in oncology and autoimmune and inflammatory diseases","volume":"647","author":"Oflazoglu","year":"2009","journal-title":"Adv Exp Med Biol."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0092-8674(93)90361-S","article-title":"CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF","volume":"73","author":"Smith","year":"1993","journal-title":"Cell"},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"R6-20230908","first-page":"223","article-title":"Clinical, histopathologic, and immunohistochemical correlations in leukemia cutis","volume":"13","author":"Su","year":"1994","journal-title":"Semin Dermatol."},{"key":"R7-20230908","first-page":"27","article-title":"Leukemia cutis\u2014epidemiology, clinical presentation, and differential diagnoses","volume":"10","author":"Wagner","year":"2012","journal-title":"J der Deutschen Dermatologischen Gesellschaft."},{"key":"R8-20230908","first-page":"ECR13","article-title":"Leukaemia cutis: clinical features and treatment strategies","volume":"87","author":"Zweegman","year":"2002","journal-title":"Haematologica"},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood.V81.12.3388.3388","article-title":"Biologic characteristics of acute leukemia after myelodysplastic syndrome","volume":"81","author":"Masuya","year":"1993","journal-title":"Blood"},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clml.2012.12.006","article-title":"CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes","volume":"13","author":"Zheng","year":"2013","journal-title":"Clin Lymphoma, Myeloma Leukemia."},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3109\/10428194.2012.728596","article-title":"CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis","volume":"54","author":"Fathi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamadermatol.2013.5741","article-title":"A case of refractory Sezary syndrome with large-cell transformation responsive to brentuximab vedotin","volume":"150","author":"Corey","year":"2014","journal-title":"JAMA Dermatol."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous t-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamadermatol.2014.1629","article-title":"Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome","volume":"151","author":"Mehra","year":"2015","journal-title":"JAMA Dermatol."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clim.1998.4636","article-title":"CD30 in normal and neoplastic cells","volume":"90","author":"Chiarle","year":"1999","journal-title":"Clin Immunol."},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/10428194.2010.550072","article-title":"Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms","volume":"52","author":"Valent","year":"2011","journal-title":"Leuk Lymphoma."},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/jcp.55.3.162","article-title":"Hodgkin's lymphoma: the pathologist's viewpoint","volume":"55","author":"Pileri","year":"2002","journal-title":"J Clin Pathol."},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood.V74.5.1678.1678","article-title":"BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope","volume":"74","author":"Schwarting","year":"1989","journal-title":"Blood"},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.4049\/jimmunol.169.4.1784","article-title":"CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses","volume":"169","author":"Chan","year":"2002","journal-title":"J Immunol."},{"key":"R22-20230908","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"R23-20230908","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1701554","article-title":"B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome","volume":"23","author":"Gross","year":"1999","journal-title":"Bone Marrow Transpl."},{"key":"R24-20230908","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1200\/JCO.2011.37.7101","article-title":"Donor-derived lymphomatoid papulosis in a stem-cell transplantation recipient","volume":"29","author":"Camp","year":"2011","journal-title":"J Clin Oncol."},{"key":"R25-20230908","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1684\/ejd.2009.0746","article-title":"Lymphomatoid papulosis after allogenic stem cell transplantation","volume":"19","author":"Kim","year":"2009","journal-title":"Eur J Dermatol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201705000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:01:22Z","timestamp":1694149282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201705000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000755","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}